CSS
CLSD

Cubist Systematic Strategies’s Clearside Biomedical CLSD Stock Holding History

Cubist Systematic Strategies’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,069
Closed -$20.4K – 3042
2024
Q3 		$20.4K Buy
+1,069
New +$18.2K ﹤0.01% 2816
2024
Q2 		– Sell
-1,638
Closed -$37.6K – 3129
2024
Q1 		$37.6K Buy
+1,638
New +$35.3K ﹤0.01% 3416
2022
Q2 		– Sell
-1,280
Closed -$44K – 4379
2022
Q1 		$44K Sell
1,280
-2,250
-64% -$67.3K ﹤0.01% 3405
2021
Q4 		$146K Sell
3,530
-1,801
-34% -$117K ﹤0.01% 3113
2021
Q3 		$480K Buy
5,331
+3,554
+200% +$314K 0.01% 2063
2021
Q2 		$130K Buy
1,777
+404
+29% +$18.8K ﹤0.01% 2680
2021
Q1 		$51K Buy
+1,373
New +$68.9K ﹤0.01% 2732
2018
Q4 		– Sell
-573
Closed -$53K – 2084
2018
Q3 		$53K Buy
573
+546
+2,022% +$64.9K ﹤0.01% 1700
2018
Q2 		$4K Sell
27
-791
-97% -$133K ﹤0.01% 1744
2018
Q1 		$132K Buy
+818
New +$99.6K 0.01% 1535

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cubist Systematic Strategies's CLSD Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 1,069 shares — an estimated $20.4K sold.

Cubist Systematic Strategies first reported a position in CLSD in Q1 2018 and held it in 10 quarters. The position peaked at $480K in Q3 2021. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,069 Clearside Biomedical shares in Q4 2024, an estimated $20.4K.
  • Cubist Systematic Strategies first reported a position in Clearside Biomedical in Q1 2018 and held it in 10 quarters.
  • Cubist Systematic Strategies's Clearside Biomedical position peaked at $480K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.